IMPACT OF NEXTSENSE INSTITUTE RESEARCH IN THE FIELD OF SENSORY DISABILITIES
With
Professor Greg Leigh AO,
Director, NextSense Institute, Australia &
Conjoint Professor,
Macquarie School of Education
Macquarie University, Sydney
RESEARCH IMPACT
Filmed in Sydney, Australia | June 2025
NextSense, formerly known as the Royal Institute for Deaf & Blind Children, is a not-for-profit established in 1860 that provides dedicated, innovative, and customised services aimed at breaking down barriers for children, adults and families of people with hearing or vision loss.
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations.
The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
The Institute offers a range of educational programs, including postgraduate degrees, professional development courses, and customised training for educators, therapists, health professionals, and carers. One of its flagship programs is the Master of Disability Studies, delivered in affiliation with Macquarie University, which prepares professionals to work with individuals who are deaf, hard of hearing, blind, or have low vision.
Professor Greg Leigh AO, Director NextSense Institute, talks about 3 areas of research that have had significant impact in it’s delivery of programs and services to Australians and countries across the world.
Through this research, NextSense Institute aims to break down barriers and redefine what is possible for individuals with sensory disabilities, fostering inclusion and enhancing quality of life.
Source: Written by AUDIENCED using source information from the NextSense website
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
-
Big data research in maternal, perinatal and renal health epidemiology
Dr Erandi Hewawasam is a Research Fellow at the National Perinatal Epidemiology and Statistics Unit within the Centre for Big Data Research in Health at University of New South Wales (UNSW). Her work focuses on maternal and reproductive health, chronic diseases (e.g., kidney disease, endometriosis), and early-life outcomes. She is the Program Manager for the Fertility Medicine Data Asset for Australia (FM-DATA), an MRFF-funded national infrastructure project linking fertility, hospital, Medicare, pharmaceutical, and perinatal datasets covering more than 40 million individuals. She also coordinates the Early Life Course Platform, integrating around 20 New South Wales and Australian federal administrative datasets to support population health research.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
